[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648128":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":29,"centralContacts":35,"locations":41,"responsibleParty":125,"collaborators":29,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":29,"eligibilityCriteria":133,"healthyVolunteers":129,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":29,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Axsome Therapeutics, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Solriamfetol Dose A","EXPERIMENTAL","Up to 6 weeks",[13],"Drug: Solriamfetol Dose A",{"label":15,"type":10,"description":11,"interventionNames":16},"Solriamfetol Dose B",[17],"Drug: Solriamfetol Dose B",{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo","PLACEBO_COMPARATOR","Up to weeks",[23],"Drug: Placebo",[25,30,32],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Solriamfetol capsules, taken once daily",[9],null,{"type":26,"name":15,"description":27,"armGroupLabels":31,"otherNames":29},[15],{"type":26,"name":19,"description":33,"armGroupLabels":34,"otherNames":29},"Placebo capsules, taken once daily",[19],[36],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"Study Director","CONTACT","929-618-4421","akim@axsome.com",[42,56,65,74,82,90,98,107,116],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":29},"Clinical Research Site","RECRUITING","Dothan","Alabama","36303","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-85.39049,31.22323,{"lat":54,"lon":53},{"facility":43,"status":44,"city":57,"state":58,"zip":59,"country":48,"countryCode":49,"cosmosGeoPoint":60,"geoPoint":64,"contacts":29},"Little Rock","Arkansas","72211",{"type":51,"coordinates":61},[62,63],-92.28959,34.74648,{"lat":63,"lon":62},{"facility":43,"status":44,"city":66,"state":67,"zip":68,"country":48,"countryCode":49,"cosmosGeoPoint":69,"geoPoint":73,"contacts":29},"Coral Gables","Florida","33146",{"type":51,"coordinates":70},[71,72],-80.26838,25.72149,{"lat":72,"lon":71},{"facility":43,"status":44,"city":75,"state":67,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":29},"Jacksonville","32256",{"type":51,"coordinates":78},[79,80],-81.65565,30.33218,{"lat":80,"lon":79},{"facility":43,"status":44,"city":83,"state":67,"zip":84,"country":48,"countryCode":49,"cosmosGeoPoint":85,"geoPoint":89,"contacts":29},"Maitland","32751",{"type":51,"coordinates":86},[87,88],-81.36312,28.62778,{"lat":88,"lon":87},{"facility":43,"status":44,"city":91,"state":67,"zip":92,"country":48,"countryCode":49,"cosmosGeoPoint":93,"geoPoint":97,"contacts":29},"Orlando","32801",{"type":51,"coordinates":94},[95,96],-81.37924,28.53834,{"lat":96,"lon":95},{"facility":43,"status":44,"city":99,"state":100,"zip":101,"country":48,"countryCode":49,"cosmosGeoPoint":102,"geoPoint":106,"contacts":29},"Bardstown","Kentucky","40004",{"type":51,"coordinates":103},[104,105],-85.4669,37.80923,{"lat":105,"lon":104},{"facility":43,"status":44,"city":108,"state":109,"zip":110,"country":48,"countryCode":49,"cosmosGeoPoint":111,"geoPoint":115,"contacts":29},"Memphis","Tennessee","38119",{"type":51,"coordinates":112},[113,114],-90.04898,35.14953,{"lat":114,"lon":113},{"facility":43,"status":44,"city":117,"state":118,"zip":119,"country":48,"countryCode":49,"cosmosGeoPoint":120,"geoPoint":124,"contacts":29},"Austin","Texas","78759",{"type":51,"coordinates":121},[122,123],-97.74306,30.26715,{"lat":123,"lon":122},{"type":126,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100648128","phase-3-a-study-to-assess-the-efficacy-and-safety-of-solriamfetol-in-adolescents-with-adhd-100648128",false,"NCT07717892","A Study to Assess the Efficacy and Safety of Solriamfetol in Adolescents With ADHD","A Phase 3, Randomized, 6-Week, Double-blind, Placebo- Controlled Trial of Solriamfetol in Adolescents Aged 12 to \u003C18 Years With Attention Deficit Hyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n* Male or female, aged 12 to \\\u003C18 years.\n* Primary diagnosis of ADHD according to DSM-5 criteria.\n* Has parents\u002Flegal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures.\n\nExclusion Criteria:\n\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","ALL","12 Years","17 Years",{"count":138,"type":139},468,"ESTIMATED","INTERVENTIONAL",[142],"PHASE3","This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to \\\u003C18 years with ADHD.",[145],"ADHD",[147,145,148,149,150,151,152],"Attention deficit hyperactivity disorder","Sunosi","Solriamfetol","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","2026-07-16",{"date":155,"type":156},"2026-07-21","ACTUAL",{"date":158,"type":156},"2026-06-25",{"date":160,"type":139},"2028-06-30",{"name":5,"class":6},9]